汉防己甲素联合顺铂及新型Hsp90蛋白抑制剂对人乳腺癌细胞作用的研究
|
摘要
化学药物治疗是目前国际上临床恶性肿瘤治疗的主要手段之一,但由于肿瘤细胞的耐药性使得化疗治疗没有达到预期的临床效果,提高肿瘤对化疗药物的敏感性成为恶性肿瘤治疗的关键。新兴起的靶向治疗前景很广,该方法基于基因或者受体的表达来选择用药,选择性强,所以疗效更好,而毒性更低,但目前还处于起步阶段,虽然它很有潜力,但并不能代替手术、化疗和放疗等传统的肿瘤治疗方法。
为了提高癌细胞对化疗药物的敏感性,探索新型Hsp90抑制剂SNX-2112抗肿瘤的作用机制,本研究以人乳腺癌细胞MDA-MB-231、MCF-7、MCF-7/ADR为模型,采用原子力显微术、共聚焦显微术、MTT法、Annexin-v/PI荧光染色法、流式细胞技术和Western Blot等方法,对药物改变癌细胞的表面结构和相关蛋白进行检测,获得了以下具有创新性的成果：
1、低浓度的联合用药作用乳腺癌细胞24小时,细胞膜表面结构被破坏,产生孔洞；作用48小时细胞被严重破坏使细胞周期在S期比例增加到51.7%±0.30%。联合用药通过改变细胞膜的结构对癌细胞进行有效杀伤,使得顺铂对癌细胞作用的IC50值由26.33μmol/L降低到13.32μmol/L,提高了癌细胞对抗癌药物的敏感性,抑制肿瘤细胞生长。
2、新型Hsp90抑制剂SNX-2112能有效的抑制MCF-7/ADR细胞的生长,10μmol/L的SNX-2112作用MCF-7/ADR细胞48小时的抑制率为(63.6±8.2)%,凋亡率为(53.4±7.3)%。SNX-2112抑制Hsp90的活性,诱导Hsp90受体蛋白降解,影响细胞对DNA修复酶PARP的正常表达,诱导乳腺癌细胞凋亡,且耐药株并没有通过P-gp糖蛋白对SNX-2112发生耐药作用,降低SNX-2112的药效。
采用原子力显微术探测细胞的形貌和表面结构的变化,结合生物技术手段对药物作用癌细胞进行细胞毒性、相关蛋白的检测,可以直观的看到药物对细胞的作用效果。联合用药提高癌细胞对化疗药物的敏感性,减少耐药性发生。新型Hsp90抑制剂SNX-2112诱导癌细胞凋亡,表现出良好的靶向作用效果,为抗癌药物的研究提供新的实验依据。
Chemotherapy is a primary mean of clinical cancer treatment at pressent. However, due to drug resistance of tumor cells, chemotherapy was not able to reach the desirably clinical effect. So improved tumor sensitivity to chemotherapeutic drugs was a key problem to cancer treatment. Recently, the new method of targeted therapy is based on the expression of genes or receptor to selective drugs, so the efficacy will be better and toxicity will be lower. Targeted therapy application was at primary stage now. Although it has potential prospects, but can not replace surgery、chemotherapy、radiotherapy treatment and other traditional treatment for cancer at present.
In order to improve the sensitivity of cancer cells to chemotherapeutic drugs, and explore anti-tumor mechanism of the novel Hsp90 inhibitor SNX-2112, human breast cancer cells:MDA-MB-231、MCF-7 and MCF-7/ADR were selected as models in this study. Atomic force microscopy、confocal microscopy、MTT method、Annexin-v/PI fluorescence staining、flow cytometry and Western Blot methods were used to detect changes in the surface structure of cancer cells and drug-related protein, and the following results were obtained:
1、The surface structure of tumor cells were damaged when treated with tetrandrine in low concentration at 24h and 48h. The S phase of cell cycle percentage was increased from 30.5%±0.30% to 51.7%±0.30%. Combination therapy is a way to reduce the concentration of cisplatin IC50 reduced from 26.33μmol/L to 13.32μmol/L. It was able to improve the sensitivity of tumors to chemotherapeutic drugs treatment, inhibit tumor growth.
2、A novel Hsp90 inhibitor SNX-2112 can effectively inhibit the growth of MCF-7/ADR cells and the activity of receptor protein. MCF-7/ADR cell was treated with 10μmol/L SNX-2112 for 48 hours. The inhibition rate was (63.6±8.2)%, and apoptotic rate was (53.4±7.3)%. SNX-2112 can induce degradation in Hsp90 and apoptosis in breast cancer cells. It changed the normal expression of DNA repair enzyme PARP of cancer cell. The drug resistant effect of SNX-2112 is not effected by the glycoprotein expression.
Atomic force microscopy and other biotechnology tools were used to detect the changes in the surface structure and morphology、toxicity and drug-related protein of tumor cells. We can see the effect of drugs on cells in visualization. Combination treatment was able to improve the sensitivity of cancer cells, and reduce the occurrence of drug resistance. SNX-2112 is a good effect of targeted therapy drugs, and is able to induce apoptosis in cancer cells. This study provides a new experimental reference for anti-cancer drug research.
为了提高癌细胞对化疗药物的敏感性,探索新型Hsp90抑制剂SNX-2112抗肿瘤的作用机制,本研究以人乳腺癌细胞MDA-MB-231、MCF-7、MCF-7/ADR为模型,采用原子力显微术、共聚焦显微术、MTT法、Annexin-v/PI荧光染色法、流式细胞技术和Western Blot等方法,对药物改变癌细胞的表面结构和相关蛋白进行检测,获得了以下具有创新性的成果：
1、低浓度的联合用药作用乳腺癌细胞24小时,细胞膜表面结构被破坏,产生孔洞；作用48小时细胞被严重破坏使细胞周期在S期比例增加到51.7%±0.30%。联合用药通过改变细胞膜的结构对癌细胞进行有效杀伤,使得顺铂对癌细胞作用的IC50值由26.33μmol/L降低到13.32μmol/L,提高了癌细胞对抗癌药物的敏感性,抑制肿瘤细胞生长。
2、新型Hsp90抑制剂SNX-2112能有效的抑制MCF-7/ADR细胞的生长,10μmol/L的SNX-2112作用MCF-7/ADR细胞48小时的抑制率为(63.6±8.2)%,凋亡率为(53.4±7.3)%。SNX-2112抑制Hsp90的活性,诱导Hsp90受体蛋白降解,影响细胞对DNA修复酶PARP的正常表达,诱导乳腺癌细胞凋亡,且耐药株并没有通过P-gp糖蛋白对SNX-2112发生耐药作用,降低SNX-2112的药效。
采用原子力显微术探测细胞的形貌和表面结构的变化,结合生物技术手段对药物作用癌细胞进行细胞毒性、相关蛋白的检测,可以直观的看到药物对细胞的作用效果。联合用药提高癌细胞对化疗药物的敏感性,减少耐药性发生。新型Hsp90抑制剂SNX-2112诱导癌细胞凋亡,表现出良好的靶向作用效果,为抗癌药物的研究提供新的实验依据。
Chemotherapy is a primary mean of clinical cancer treatment at pressent. However, due to drug resistance of tumor cells, chemotherapy was not able to reach the desirably clinical effect. So improved tumor sensitivity to chemotherapeutic drugs was a key problem to cancer treatment. Recently, the new method of targeted therapy is based on the expression of genes or receptor to selective drugs, so the efficacy will be better and toxicity will be lower. Targeted therapy application was at primary stage now. Although it has potential prospects, but can not replace surgery、chemotherapy、radiotherapy treatment and other traditional treatment for cancer at present.
In order to improve the sensitivity of cancer cells to chemotherapeutic drugs, and explore anti-tumor mechanism of the novel Hsp90 inhibitor SNX-2112, human breast cancer cells:MDA-MB-231、MCF-7 and MCF-7/ADR were selected as models in this study. Atomic force microscopy、confocal microscopy、MTT method、Annexin-v/PI fluorescence staining、flow cytometry and Western Blot methods were used to detect changes in the surface structure of cancer cells and drug-related protein, and the following results were obtained:
1、The surface structure of tumor cells were damaged when treated with tetrandrine in low concentration at 24h and 48h. The S phase of cell cycle percentage was increased from 30.5%±0.30% to 51.7%±0.30%. Combination therapy is a way to reduce the concentration of cisplatin IC50 reduced from 26.33μmol/L to 13.32μmol/L. It was able to improve the sensitivity of tumors to chemotherapeutic drugs treatment, inhibit tumor growth.
2、A novel Hsp90 inhibitor SNX-2112 can effectively inhibit the growth of MCF-7/ADR cells and the activity of receptor protein. MCF-7/ADR cell was treated with 10μmol/L SNX-2112 for 48 hours. The inhibition rate was (63.6±8.2)%, and apoptotic rate was (53.4±7.3)%. SNX-2112 can induce degradation in Hsp90 and apoptosis in breast cancer cells. It changed the normal expression of DNA repair enzyme PARP of cancer cell. The drug resistant effect of SNX-2112 is not effected by the glycoprotein expression.
Atomic force microscopy and other biotechnology tools were used to detect the changes in the surface structure and morphology、toxicity and drug-related protein of tumor cells. We can see the effect of drugs on cells in visualization. Combination treatment was able to improve the sensitivity of cancer cells, and reduce the occurrence of drug resistance. SNX-2112 is a good effect of targeted therapy drugs, and is able to induce apoptosis in cancer cells. This study provides a new experimental reference for anti-cancer drug research.
引文
[1]刘延辉,王弘,孙大亮,等.原子力显微镜及其在各个研究领域的应用.科技导报2003,9-11.
[2]白春礼.扫描隧道显微术及其应用.上海,上海科学技术出版社,1992.
[3]Birmig G, Quate CF, Gerber C. Atomic force microscope. Phys Rev Lett,1986,56: 930-933.
[4]Dufrene YF. Towards nanomicrobiology using atomic force microscopy. Nature Reviews Microbiology 2008; 6(9):674-680.
[5]Sun P, Laforge FO, Mirkin MV. Scanning electrochemical microscopy in the 21st century. Physical Chemistry Chemical Physics 2007; 9(7):802-823.
[6]De Feyter S, Gesquiere A, Abdel-Mottaleb MM, Grim PCM, De Schryver FC, Meiners C, Sieffert M, Valiyaveettil S, Mullen K. Scanning tunneling microscopy:A unique tool in the study of chirality, dynamics, and reactivity in physisorbed organic monolayers. Accounts of Chemical Research 2000; 33(8):520-531.
[7]Poggi MA, Gadsby ED, Bottomley LA, King WP, Oroudjev E, Hansma H. Scanning probe microscopy. Analytical Chemistry 2004; 76(12):3429-3443.
[8]鲍幸峰,方积年.原子力显微镜在生物大分子结构研究中的应用进展.分析化学2000；28(10)：1300-1307.
[9]Baldwin PM, Frazier RA, Adler J, Glasbey TO, Keane MP, Roberts CJ, Tendler SJB, Davies MC, Melia CD.Surface imaging of thermally sensitive particulate and fibrous materials with the atomic force microscope:a novel sample preparation method. J Microsc.1996,184(2):75-80.
[10]Heymann JB, Muller DJ, Landau E, et al. Charting the surfaces of purple membrane. J Struct Biol 1999; 128(3):243-249.
[11]Engel A, Schoenenberger CA, Muller DJ. High-resolution imaging of native biological sample surfaces using scanning probe microscopy. Curr Opin Struct Biol 1997; 7(2):279-284.
[12]Hansma HG. Varieties of imaging with scanning probe microscopes. Proceedings of the National Academy of Sciences of the United States of America 1999; 96(26): 14678-14680.
[13]Henderson E, Haydon PG, Sakaguchi DS. Actin Filament Dynamics in Living Glial-Cells Imaged by Atomic Force Microscopy. Science 1992; 257(5078): 1944-1946.
[14]Pincet F, Husson J. The solution to the streptavidin-biotin paradox:The influence of history on the strength of single molecular bonds. Biophysical Journal 2005; 89(6): 4374-4381.
[15]Thomson NH, Fritz M, Radmacher M, Cleveland JP, Schmidt CF, Hansma PK. Protein tracking and detection of protein motion using atomic force microscopy. Biophysical Journal 1996; 70(5):2421-2431.
[16]Drake B, Prater CB, Weisenhorn AL, Gould SAC, Albrecht TR, Quate CF, Cannell DS, Hansma HG, Hansma PK. Imaging Crystals, Polymers, and Processes in Water with the Atomic Force Microscope. Science 1989; 243(4898):1586-1589.
[17]Muller DJ, Baumeister W, Engel A. Conformational change of the hexagonally packed intermediate layer of Deinococcus radiodurans monitored by atomic force microscopy. Journal of Bacteriology 1996; 178(11):3025-3030.
[18]O'Reilly M, McDonnell L, O'Mullane J. Quantification of red blood cells using atomic force microscopy. Ultramicroscopy 2001; 86(1-2):107-112.
[19]Melling M, Hochmeister S, Blumer R, Schilcher K, Mostler S, Behnam M, Wilde J, Karimian-Teherani D. Atomic force microscopy imaging of the human trigeminal ganglion. Neuroimage 2001; 14(6):1348-1352.
[20]Melling M, Karimian-Teherani D, Behnam M, Mostler S. Morphological study of the healthy human oculomotor nerve by atomic force microscopy. Neuroimage 2003; 20(2):795-801.
[21]Dvorak JA. The application of atomic force microscopy to the study of living vertebrate cells in culture. Methods 2003; 29(1):86-96.
[22]Haberle W, Horber JKH, Ohnesorge F, Smith DPE, Binnig G. Insitu Investigations of Single Living Cells Infected by Viruses. Ultramicroscopy 1992; 42: 1161-1167. [23] Ohnesorge FM, Horber JKH, Haberle W, Czerny CP, Smith DPE, Binnig G. AFM review study on pox viruses and living cells. Biophysical Journal 1997; 73(4): 2183-2194.
[24]Berdyyeva T, Woodworth CD, Sokolov I. Visualization of cytoskeletal elements by the atomic force microscope. Ultramicroscopy 2005; 102(3):189-198.
[25]Takeuchi M, Miyamoto H, Sako Y, Komizu H, Kusumi A. Structure of the erythrocyte membrane skeleton as observed by atomic force microscopy. Biophysical Journal 1998; 74(5):2171-2183.
[26]Ke C, Jiang Y, Mieczkowski PA, Muramoto GG, Chute JP, Marszalek PE. Nanoscale detection of ionizing radiation damage to DNA by atomic force microscopy. Small 2008; 4(2):288-294.
[27]袁倬斌,王月伶,张君,吕元琦.碳纳米管在电分析中的应用.化学通报2004；67(7)：473-476.
[28]彭章泉,唐智勇,汪尔康.化学力显微镜针尖修饰技术研究新进展.分析化学 2000；28(5)：644-648.
[29]Radmacher M, Fritz M, Cleveland JP, Walters DA, Hansma PK. Imaging adhesion forces and elasticity of lysozyme adsorbed on mica with the atomic force microscope.10 1994; 10:3809-3814.
[30]Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90:the vulnerable chaperone. Drug Discovery Today 2004;9 (20):881-8.
[31]Tissieres A, Mitchell HK, Tracy UM. Protein synthesis in salivary glands of Drosophila melanogaster:relation to chromosome puffs.J Mol Biol 1974;84 (3):389-98.
[32]Zuehlke A, Johnson JL. Hsp90 and cochaperones twist the functions of diverse client proteins. Biopolymers 2009.
[33]Garrido C, Gurbuxani S, Ravagnan L, Kroemer G.Heat shock proteins: Endogenous modulators of apoptotic cell death. Biochemical and Biophysical Research Communications 2001;286 (3):433-42.
[34]Richter-Landsberg C, Goldbaum O. Stress proteins in neural cells:functional roles in health and disease. Cellular and Molecular Life Sciences 2003;60 (2):337-49.
[35]Paroo Z, Haist JV, Karmazyn M, Noble EG.Exercise improves postischemic cardiac function in males but not females-Consequences of a novel sex-specific heat shock protein 70 response. Circulation Research 2002;90 (8):911-7.
[36]Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90:small-molecule inhibitors and their clinical development. Current Opinion in Pharmacology 2008;8 (4):3 70-4.
[37]Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3 (5):301-23.
[38]Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP Crystal structure of an Hsp90-geldanamycin complex:targeting of a protein chaperone by an antitumor agent. Cell 1997;89(2):239-50.
[1]Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, et al:Cancer statistics,2009[J]. A Cancer Journal for Clinicians,2009,59:225-249.
[2]Cleator S,Heller W,Coombes KC.Triple-negative breast canceraherapeutic options[J].Lancet Oncol,2007,8(3):235-244.
[3]Finn RS,Dering J,Ginther C, et al.Dasatinib,an orally active small molecule inhibitor of both the src and abl kinases,selectively inhibits growth of basal-type/ "triple-negative" breast cancer cell lines growing in vitro[J]. Breast Cancer Res Treat,2007,105(3):319-326.
[4]Dizdar O,Dede D S,Bulut N,et al.Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines[J].Breast Cancer Res Treat,2008.107(2):303-303.
[5]Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
[6]Miller KD,Chap LI, Holmes FA,et al. Randomized phase Ⅲ trial of capecitabine compared-with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer[J].J Clin Oncol,2005.23(4):792-799.
[7]Kennedy RD,Quinn JE,Mullan PB,et al.The role of BRCA1 in the cellular respo-nse to chemotherapy [J]. J Natl Cancer Inst,2004,96(22):1659-1668.
[8]Farmer H,McCabe N,Lord CJ;et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J].Nature,2005,434(7035):917-921.
[9]Turner N,Tut t A,Ashwort h A.Targeting the DNA repair defect of BRCA tumors [J]. Curr Opin Pharmacol,2005(4),5:388-393.
[10]De, Soto JA,Deng CX.PARP-1 inhibitors:are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?[J].Int J Med Sci;2006,3 (4):117-123:
[11]于超,吴诚义Basal—llke型乳腺癌的研究发展[J].中国普通外科杂志,2009,18(5)：498—501.
[12]Pesic M, M arkovic JZ, J ankovic D, et al. Induced resistance in the human non small cell lung carcinoma (NC 12 H460) cell line in vitro by anticancer drug [J]. J Chem other,2006,18 (1):66-73.
[13]Miguel A. Fuertes, Carlos Alonso, and Jose. M. Perez.Biochemical modulation of cisplatin mechanisms of action:enhancement of antitumor activity an circumvention of drug resistance [J].Chemical Reviews,2003,103(3):646-660.
[14]徐兵河.2009年《NCCN乳腺癌临床实践指南》(中国版)重点内容解读[J].中华乳腺病杂志：电子版,2009,3(4)：375-380.
[15]Loic Le Marchand, Suzanne P Murphy, Jean H Hankin et al.Intake of flavonoids and lung cancer[J].National Cancer Institute,2000.92(2),154-160.
[16]Fuertes MA,Alonso C,Perez JM.Biochemical modulation of cisplatin mecha-nisms of action:enhancement of antltumor activity and circumvention of drug Resistance[J].Chem Rev,2003,103(3):646-660.
[17]Millikan RC,Newman B,Tse CK,et al.Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat,2008,109(1):123-139.
[18]Rakha EA, El-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J]. Cancer,2007,109(1):25-32.
[19]Perou CM,Sorlie T,Eisem MB,et al.Molecular portraits of human breast tumors [J]. Nature,2000,406(6797):747-752.
[20]Hatzopoulos S,Di Stefano M,Campbell KC,et al.Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions[J]. Audiology,2001,40(5):253-264.
[21]Liedert B,Matema V,Schadendorf D,et al.Over-expression of cMOAT (MRP2/ ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin[J].invest Dermatol, 2003,121 (1):172-176.
[22]Yo shimura N,Kudoh S,Mukohara T,et al.Phase Ⅱ study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer [J]. Br J Cancer,2004,90(6):1184-1189.
[23]Chiu-Yin KWAN, FI ACHIKE. Tetrandrine and related bisbenzylis oquinoline alkaloids from medicinal herbs:cardiovascular effects and mechanisms of action[J]. Acta Pharmacologica Sinica,2002,23 (12):1057.
[24]Chen Y J, Dai Y S, Chen B F, et al. The effect of tetrandrineand extracts of Centella asiatice on acute radiation dermatitis in rats [J]. Biol Pharm Bull,1999,22(7): 703-706.
[25]Fu LW,Deng ZA, FanW. Screening and discovery of novel MDR modifiers from naturally occurring bisbenzylisoquinoline alkaloids [J]. Anticancer Research,2001, 21(4A):2273.
[26]Xueming Zhu, Meihua Sui,Weimin Fan. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel [J]. Anticancer Research,2005,25 (3B):1953-1962.
[27]Fu LW, Zhang Y M,Liang YJ. Multidrug resistance of tumor cells was reversed by tetrandrine in vitro and in xenograft derived from human breast cancer MCF-7/adr cells [J]. European Journal of Cancer,2002,38(3):418.
[28]Jia Wei, Baorui Liu, Lifeng Wang, et al. Synergistic in teraction between tetrandrine and chemotherapeutic agents and influence of tentrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines [J] Cancer Chemotherapy and Pharmacology,2007,60 (2):703-711.
[29]Satadal Chatterjee, Haruyo Hirota, Charles A, et al. Hypersensitivity to DNA cross-1 inking agents associated with up-regulation of glucose-regulated stress protein GRP78[J]. Cancer Research,1997,57(22):5112-5116.
[30]何琪扬,孟凡宏,张冯卿.粉防己碱和蝙蝠葛碱减低抗三杉酷碱的人白血HL-60细胞对阿霉素的抗性[J].中国药理学报,1996,17(2)：179-181.
[31]何琪扬,张鸿卿,庞大本,等.抗三尖杉酷碱的HL-60细胞抗粉防己碱诱导的细胞凋亡[J].中国药理学报,1996,17(6)：545-549.
[32]许文林,敖忠芳,陈玉心,等.汉防己甲素对柔红霉素和长春新碱增效作用的实验研究[J].中华血液学杂志,1994,15(5)：256-257.
[33]许文林,敖忠芳,陈宝安.汉防己甲素逆转血液系统肿瘤细胞多药耐药的临床研究[[J].中华内科杂志,2001,40(9)：631-633.
[34]Xu WL,Shen HL,Ao ZF, et al.Combination of tetrandrine as a potential-reversing agent with daunorubicin,etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia[J]:Leak Res,2006,30(4):407-413.
[35]DUFRENE Y F. Using nanotechniques to explore microbial surfaces [J]. Nature Reviews Microbiology,2004,2(6):451-460.
[36]GREENLEAF W J, WOODSI DE M T, BLOCK SM. High-resolution, single molecule measurements of biomolecular motion [J]. Annu Rev Biophys Biomol Struct,2007,36:171-19.
[37]JIN Hua, XING Xiaobo, ZHAO Hongxia, et al. Detection of erythrocytes influenced by aging and type 2 diabetes using atomic force microscope[J].Biochemical and Biophysical Research Communications,2010,391 (4):1698-1702.
[38]CAI Xiaofang, XING Xiaobo, CAI Jiye,et al.Connection between biomechanics and cytoskeleton structure of lymphocyte and Jurkat cells:An AFM study [J].Micron, 2010,41(3):257-262.
[39]HU Mingqian, WANG Jiongkun, CAI Jiye, et al. Nanostructure and force spectroscopy analysis of human peripheral blood CD4+T cells using atomic force microscopy[J].Biochem Biophys Res Commun,2008,374 (1):90-94.
[40]Gabriel Y.H.Lee,Chwee T. Lim.Biomechanics approaches to studying human diseases[J].Trends in Biot-echnology,2007,25(3):111-118.
[41]Subra Suresh.Biomechanics and biophysics of cancer cells[J].Acta Materialia,2007,55(12):3989-4014.
[42]Engin Ulukaya, Ferda Ozdikicioglu, Arzu Yilmaztepe Oral, et al. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested[J]. Toxicology in Vitro,2008,22(1):232-239.
[43]赵斌,葛金芳,朱娟娟,等.小议在MTT法测细胞增殖抑制率中IC50的计算方法[J].安徽医药,2007,11(9)：834-836.
[44]Jin Chen, Xing-Hua Feng, Jian Shi. The anti-nociceptive effect of BmK AS, a scorpion active polypeptide, and the possible mechanism on specifically modulating voltage-gated Na+ currents in primary afferent neurons [J].Peptides,2006,27(9): 2182-2192.
[45]Brabec V. DNA modifications by antitumor platinum and rugthenium compounds their recognition and repair [J]. Prog Nucleic Acid Res Mol Biol,2002,71:1-68.
[46]Lean Teik Ng, Lien-Chai Chiang, Yu-Tseng Lin,et al. Antiproliferative and apoptotic effects of Tetrandrine on different human heaptoma cell lines[J]. The American Journal of Chinese Medicine,2006,34(1):125-135.
[47]Jia Wei, Baorui Liu,Lifeng Wang,et al. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines[J]. Cancer Chemotherapy and Pharmacology,2007,60:703-711.
[48]Jinyi Wang,Zongfang Wan. Atomic force microscope study of tumor cell membranes following treatment with anti-cancer drugs[J]. Biosensors and Bioelectronics,2009,25 (4):721-727.
[49]Shripad Kondra,Jummi Laishram. Integration of confocal and atomic force microscopy images[J].Journal of Neuroscience Methods,2009,177(1):94-107.
[1]张丽龙.新型异黄酮化合物F11的药物设计、抗癌活性与遗传生殖毒性研究[D].北京：第三军医大学,2007.
[2]Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ,Workman P. Anticancer agents targetingsignaling molecules and cancer cell environment:challenges for drug development?[J]. Nail Cancer Inst 1999,91:1281-1287.
[3]Nava Zaarur,Vladimir L. Gabai, John A.Targeting Heat Shock Response to Sensitize Cancer Cells to Proteasome and Hsp90 Inhibitors[J]. Cancer Res 2006;66:1783-1791
[4]Stang K, Gunther C, Fran KT, et al. Inhibition of the ubiquitin-proteosome pat hway induces differential heat shockprotein response in cardiomyocytes and renders early cardiac protection[J]. Biochem Biophys Res Commun,2002,3:542-549;
[5]Rutherford SL, Lindquist S. HSP90 as a capacitor for morphologicalevolution[J]. Nature,1998,6709:336-342;
[6]Bagatell R, Whitesell L. Altered hsp90 function in cancer:a unique therapeutic opportunity [J]. Mol Cancer Ther,2004; 8:1021-1030;
[7]Pearl LH, Prodromou C. Structure, function, and mechanism of the Hsp90 molecular chaperone[J]. Adv Protein Chem,2001,59:157-164;
[8]PrattW B. The Hsp902based chaperone system:involvement in signal transduction from a variety of hormone and growth factor receptors[J]. Proc Soc Exp B iolMed,1998,217:420-431;
[9]Workman P. Combinatorial attack on multistep oncogenesis by inhibitingthe Hsp90 molecular chaperone[J]. Cancer Lett,2004,2:149-157.
[10]Ferrarini M, Hehai S, Zocchi MR, et al. Unusual expression and localization of heat-shock proteins in human tulrlor cells [J]. Int Jcancer,1992,51(4):613-619.
[11]Kaelin WG Jr. Taking aim at novel molecular targets in cancer therapy[J].J Clin Invest,1999,104(11):1495.
[12]Ochel HJ, Schulte TW, Nguyen P, et al. The benzoquinone ansamycin geldanamycinstimulates proteolytic degradation of focal adhesion kinase [J]. Mol GenetMetab,1999,66(1):24-30.
[13]Supko JG, Hickman RL, Grever MR, et al. Precl finical pharmacologicevaluation of geldnamycin as an antitumor agent [J].Cancer Chemother Pharmaco,1995,36(4): 305-315.
[14]Kwon HJ,Yoshida M, Fukui Y, et al. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol [J]. Cancer Res,1992,24: 6926-6930.
[15]Goetz MP, Toft DO, Ames MM, et al. The Hsp90 chaperone comp lex as a novel target for cancer therapy [J]. Ann Oncol,2003,14(8):1169-1176.
[16]Schulte TW, Neckers LM.Thebenzoquinoneansamyeinl7-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin[J].Cancer Chemother Pharmacol,1998,4:273-279.
[17]Chiosis G, Tao H. Purine-scaffold Hsp90 inhibitors[J]. IDrugs,2006,11:778-782.
[18]Thomas E, Barta JM, Veal JW. Rice, et al. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90[J]. Bioorg Med Chem Lett,2008,18:3517-3521.
[19]Sarat C, Ayana S, Qing Ye, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers[J]. Clin Cancer Res,2008,1:240-248;
[20]Yutaka O, Teru H, Paul S, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK[J]. Blood, 2009,4:846-855;
[21]Sharom FJ. ABC multidrug transporters:structure, function and role in chemoresistance[J]. Pharmacogenomics Jan;2008,9:105.
[22]Stephen G. Aller1, Jodie Yu1, Andrew Ward2, et al. Structure of P-glycoprotein Reveals a Molecular Basis for PolySpecific Drug Binding[J]. Science.2009 March 27; 323(5922):1718-1722.
[23]Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter[J]. Annual Review of Biochemistry.1993;62:385-427
[24]Gatlik-Landwojtowicz E, Aanismaa P, Seelig A. Quantification and characterization of P-glycoprotein-substrate interactions[J].Biochemistry,2006 45:3020.
[25]Piskunova TS, Yurova MN, Ovsyannikov AI, et al.Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice[J]. Curr Gerontol Geriatr Res.2008:754190.
[26]Espinoza LA, Smulson ME, Chen Z. Prolonged poly(ADP-ribose) polymerase-1 activity regulates JP-8-induced sustained cytokine expression in alveolar macrophages[J]. Free radical biology & medicine,2007,42 (9):1430-40.
[27]Zerfaoui M, Suzuki Y, Naura AS, et al. Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells:Differential requirement for PARP-1 expression and interaction[J]. Cell Signal,2008.20 (1):186-94.
[28]Liu X D, Sun H, Liu G T. Tumor chemosensitization strategies based on apoptosis manipulations [J]. Chin Pharmacol Bull,2009,25(10):1261-4.
[29]Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer:drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21.
[30]Bieling P, Laan L, Schek H, Munteanu EL, Sandblad L, Dogterom M, Bruimer D, Surrey T. Reconstitution of a microtubule plus-end traeking system in vitro.Nature.2007,450(7172):1100-1105.
[31]Barta TE, Veal JM, Rice JW, et al. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett,2008,18,3517-3521;
[2]白春礼.扫描隧道显微术及其应用.上海,上海科学技术出版社,1992.
[3]Birmig G, Quate CF, Gerber C. Atomic force microscope. Phys Rev Lett,1986,56: 930-933.
[4]Dufrene YF. Towards nanomicrobiology using atomic force microscopy. Nature Reviews Microbiology 2008; 6(9):674-680.
[5]Sun P, Laforge FO, Mirkin MV. Scanning electrochemical microscopy in the 21st century. Physical Chemistry Chemical Physics 2007; 9(7):802-823.
[6]De Feyter S, Gesquiere A, Abdel-Mottaleb MM, Grim PCM, De Schryver FC, Meiners C, Sieffert M, Valiyaveettil S, Mullen K. Scanning tunneling microscopy:A unique tool in the study of chirality, dynamics, and reactivity in physisorbed organic monolayers. Accounts of Chemical Research 2000; 33(8):520-531.
[7]Poggi MA, Gadsby ED, Bottomley LA, King WP, Oroudjev E, Hansma H. Scanning probe microscopy. Analytical Chemistry 2004; 76(12):3429-3443.
[8]鲍幸峰,方积年.原子力显微镜在生物大分子结构研究中的应用进展.分析化学2000；28(10)：1300-1307.
[9]Baldwin PM, Frazier RA, Adler J, Glasbey TO, Keane MP, Roberts CJ, Tendler SJB, Davies MC, Melia CD.Surface imaging of thermally sensitive particulate and fibrous materials with the atomic force microscope:a novel sample preparation method. J Microsc.1996,184(2):75-80.
[10]Heymann JB, Muller DJ, Landau E, et al. Charting the surfaces of purple membrane. J Struct Biol 1999; 128(3):243-249.
[11]Engel A, Schoenenberger CA, Muller DJ. High-resolution imaging of native biological sample surfaces using scanning probe microscopy. Curr Opin Struct Biol 1997; 7(2):279-284.
[12]Hansma HG. Varieties of imaging with scanning probe microscopes. Proceedings of the National Academy of Sciences of the United States of America 1999; 96(26): 14678-14680.
[13]Henderson E, Haydon PG, Sakaguchi DS. Actin Filament Dynamics in Living Glial-Cells Imaged by Atomic Force Microscopy. Science 1992; 257(5078): 1944-1946.
[14]Pincet F, Husson J. The solution to the streptavidin-biotin paradox:The influence of history on the strength of single molecular bonds. Biophysical Journal 2005; 89(6): 4374-4381.
[15]Thomson NH, Fritz M, Radmacher M, Cleveland JP, Schmidt CF, Hansma PK. Protein tracking and detection of protein motion using atomic force microscopy. Biophysical Journal 1996; 70(5):2421-2431.
[16]Drake B, Prater CB, Weisenhorn AL, Gould SAC, Albrecht TR, Quate CF, Cannell DS, Hansma HG, Hansma PK. Imaging Crystals, Polymers, and Processes in Water with the Atomic Force Microscope. Science 1989; 243(4898):1586-1589.
[17]Muller DJ, Baumeister W, Engel A. Conformational change of the hexagonally packed intermediate layer of Deinococcus radiodurans monitored by atomic force microscopy. Journal of Bacteriology 1996; 178(11):3025-3030.
[18]O'Reilly M, McDonnell L, O'Mullane J. Quantification of red blood cells using atomic force microscopy. Ultramicroscopy 2001; 86(1-2):107-112.
[19]Melling M, Hochmeister S, Blumer R, Schilcher K, Mostler S, Behnam M, Wilde J, Karimian-Teherani D. Atomic force microscopy imaging of the human trigeminal ganglion. Neuroimage 2001; 14(6):1348-1352.
[20]Melling M, Karimian-Teherani D, Behnam M, Mostler S. Morphological study of the healthy human oculomotor nerve by atomic force microscopy. Neuroimage 2003; 20(2):795-801.
[21]Dvorak JA. The application of atomic force microscopy to the study of living vertebrate cells in culture. Methods 2003; 29(1):86-96.
[22]Haberle W, Horber JKH, Ohnesorge F, Smith DPE, Binnig G. Insitu Investigations of Single Living Cells Infected by Viruses. Ultramicroscopy 1992; 42: 1161-1167. [23] Ohnesorge FM, Horber JKH, Haberle W, Czerny CP, Smith DPE, Binnig G. AFM review study on pox viruses and living cells. Biophysical Journal 1997; 73(4): 2183-2194.
[24]Berdyyeva T, Woodworth CD, Sokolov I. Visualization of cytoskeletal elements by the atomic force microscope. Ultramicroscopy 2005; 102(3):189-198.
[25]Takeuchi M, Miyamoto H, Sako Y, Komizu H, Kusumi A. Structure of the erythrocyte membrane skeleton as observed by atomic force microscopy. Biophysical Journal 1998; 74(5):2171-2183.
[26]Ke C, Jiang Y, Mieczkowski PA, Muramoto GG, Chute JP, Marszalek PE. Nanoscale detection of ionizing radiation damage to DNA by atomic force microscopy. Small 2008; 4(2):288-294.
[27]袁倬斌,王月伶,张君,吕元琦.碳纳米管在电分析中的应用.化学通报2004；67(7)：473-476.
[28]彭章泉,唐智勇,汪尔康.化学力显微镜针尖修饰技术研究新进展.分析化学 2000；28(5)：644-648.
[29]Radmacher M, Fritz M, Cleveland JP, Walters DA, Hansma PK. Imaging adhesion forces and elasticity of lysozyme adsorbed on mica with the atomic force microscope.10 1994; 10:3809-3814.
[30]Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90:the vulnerable chaperone. Drug Discovery Today 2004;9 (20):881-8.
[31]Tissieres A, Mitchell HK, Tracy UM. Protein synthesis in salivary glands of Drosophila melanogaster:relation to chromosome puffs.J Mol Biol 1974;84 (3):389-98.
[32]Zuehlke A, Johnson JL. Hsp90 and cochaperones twist the functions of diverse client proteins. Biopolymers 2009.
[33]Garrido C, Gurbuxani S, Ravagnan L, Kroemer G.Heat shock proteins: Endogenous modulators of apoptotic cell death. Biochemical and Biophysical Research Communications 2001;286 (3):433-42.
[34]Richter-Landsberg C, Goldbaum O. Stress proteins in neural cells:functional roles in health and disease. Cellular and Molecular Life Sciences 2003;60 (2):337-49.
[35]Paroo Z, Haist JV, Karmazyn M, Noble EG.Exercise improves postischemic cardiac function in males but not females-Consequences of a novel sex-specific heat shock protein 70 response. Circulation Research 2002;90 (8):911-7.
[36]Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90:small-molecule inhibitors and their clinical development. Current Opinion in Pharmacology 2008;8 (4):3 70-4.
[37]Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3 (5):301-23.
[38]Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP Crystal structure of an Hsp90-geldanamycin complex:targeting of a protein chaperone by an antitumor agent. Cell 1997;89(2):239-50.
[1]Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, et al:Cancer statistics,2009[J]. A Cancer Journal for Clinicians,2009,59:225-249.
[2]Cleator S,Heller W,Coombes KC.Triple-negative breast canceraherapeutic options[J].Lancet Oncol,2007,8(3):235-244.
[3]Finn RS,Dering J,Ginther C, et al.Dasatinib,an orally active small molecule inhibitor of both the src and abl kinases,selectively inhibits growth of basal-type/ "triple-negative" breast cancer cell lines growing in vitro[J]. Breast Cancer Res Treat,2007,105(3):319-326.
[4]Dizdar O,Dede D S,Bulut N,et al.Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines[J].Breast Cancer Res Treat,2008.107(2):303-303.
[5]Miller K,Wang M,Gralow J,et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J].N Engl J Med,2007,357(26):2666-2676.
[6]Miller KD,Chap LI, Holmes FA,et al. Randomized phase Ⅲ trial of capecitabine compared-with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer[J].J Clin Oncol,2005.23(4):792-799.
[7]Kennedy RD,Quinn JE,Mullan PB,et al.The role of BRCA1 in the cellular respo-nse to chemotherapy [J]. J Natl Cancer Inst,2004,96(22):1659-1668.
[8]Farmer H,McCabe N,Lord CJ;et al.Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J].Nature,2005,434(7035):917-921.
[9]Turner N,Tut t A,Ashwort h A.Targeting the DNA repair defect of BRCA tumors [J]. Curr Opin Pharmacol,2005(4),5:388-393.
[10]De, Soto JA,Deng CX.PARP-1 inhibitors:are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?[J].Int J Med Sci;2006,3 (4):117-123:
[11]于超,吴诚义Basal—llke型乳腺癌的研究发展[J].中国普通外科杂志,2009,18(5)：498—501.
[12]Pesic M, M arkovic JZ, J ankovic D, et al. Induced resistance in the human non small cell lung carcinoma (NC 12 H460) cell line in vitro by anticancer drug [J]. J Chem other,2006,18 (1):66-73.
[13]Miguel A. Fuertes, Carlos Alonso, and Jose. M. Perez.Biochemical modulation of cisplatin mechanisms of action:enhancement of antitumor activity an circumvention of drug resistance [J].Chemical Reviews,2003,103(3):646-660.
[14]徐兵河.2009年《NCCN乳腺癌临床实践指南》(中国版)重点内容解读[J].中华乳腺病杂志：电子版,2009,3(4)：375-380.
[15]Loic Le Marchand, Suzanne P Murphy, Jean H Hankin et al.Intake of flavonoids and lung cancer[J].National Cancer Institute,2000.92(2),154-160.
[16]Fuertes MA,Alonso C,Perez JM.Biochemical modulation of cisplatin mecha-nisms of action:enhancement of antltumor activity and circumvention of drug Resistance[J].Chem Rev,2003,103(3):646-660.
[17]Millikan RC,Newman B,Tse CK,et al.Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat,2008,109(1):123-139.
[18]Rakha EA, El-Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J]. Cancer,2007,109(1):25-32.
[19]Perou CM,Sorlie T,Eisem MB,et al.Molecular portraits of human breast tumors [J]. Nature,2000,406(6797):747-752.
[20]Hatzopoulos S,Di Stefano M,Campbell KC,et al.Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions[J]. Audiology,2001,40(5):253-264.
[21]Liedert B,Matema V,Schadendorf D,et al.Over-expression of cMOAT (MRP2/ ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin[J].invest Dermatol, 2003,121 (1):172-176.
[22]Yo shimura N,Kudoh S,Mukohara T,et al.Phase Ⅱ study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer [J]. Br J Cancer,2004,90(6):1184-1189.
[23]Chiu-Yin KWAN, FI ACHIKE. Tetrandrine and related bisbenzylis oquinoline alkaloids from medicinal herbs:cardiovascular effects and mechanisms of action[J]. Acta Pharmacologica Sinica,2002,23 (12):1057.
[24]Chen Y J, Dai Y S, Chen B F, et al. The effect of tetrandrineand extracts of Centella asiatice on acute radiation dermatitis in rats [J]. Biol Pharm Bull,1999,22(7): 703-706.
[25]Fu LW,Deng ZA, FanW. Screening and discovery of novel MDR modifiers from naturally occurring bisbenzylisoquinoline alkaloids [J]. Anticancer Research,2001, 21(4A):2273.
[26]Xueming Zhu, Meihua Sui,Weimin Fan. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel [J]. Anticancer Research,2005,25 (3B):1953-1962.
[27]Fu LW, Zhang Y M,Liang YJ. Multidrug resistance of tumor cells was reversed by tetrandrine in vitro and in xenograft derived from human breast cancer MCF-7/adr cells [J]. European Journal of Cancer,2002,38(3):418.
[28]Jia Wei, Baorui Liu, Lifeng Wang, et al. Synergistic in teraction between tetrandrine and chemotherapeutic agents and influence of tentrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines [J] Cancer Chemotherapy and Pharmacology,2007,60 (2):703-711.
[29]Satadal Chatterjee, Haruyo Hirota, Charles A, et al. Hypersensitivity to DNA cross-1 inking agents associated with up-regulation of glucose-regulated stress protein GRP78[J]. Cancer Research,1997,57(22):5112-5116.
[30]何琪扬,孟凡宏,张冯卿.粉防己碱和蝙蝠葛碱减低抗三杉酷碱的人白血HL-60细胞对阿霉素的抗性[J].中国药理学报,1996,17(2)：179-181.
[31]何琪扬,张鸿卿,庞大本,等.抗三尖杉酷碱的HL-60细胞抗粉防己碱诱导的细胞凋亡[J].中国药理学报,1996,17(6)：545-549.
[32]许文林,敖忠芳,陈玉心,等.汉防己甲素对柔红霉素和长春新碱增效作用的实验研究[J].中华血液学杂志,1994,15(5)：256-257.
[33]许文林,敖忠芳,陈宝安.汉防己甲素逆转血液系统肿瘤细胞多药耐药的临床研究[[J].中华内科杂志,2001,40(9)：631-633.
[34]Xu WL,Shen HL,Ao ZF, et al.Combination of tetrandrine as a potential-reversing agent with daunorubicin,etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia[J]:Leak Res,2006,30(4):407-413.
[35]DUFRENE Y F. Using nanotechniques to explore microbial surfaces [J]. Nature Reviews Microbiology,2004,2(6):451-460.
[36]GREENLEAF W J, WOODSI DE M T, BLOCK SM. High-resolution, single molecule measurements of biomolecular motion [J]. Annu Rev Biophys Biomol Struct,2007,36:171-19.
[37]JIN Hua, XING Xiaobo, ZHAO Hongxia, et al. Detection of erythrocytes influenced by aging and type 2 diabetes using atomic force microscope[J].Biochemical and Biophysical Research Communications,2010,391 (4):1698-1702.
[38]CAI Xiaofang, XING Xiaobo, CAI Jiye,et al.Connection between biomechanics and cytoskeleton structure of lymphocyte and Jurkat cells:An AFM study [J].Micron, 2010,41(3):257-262.
[39]HU Mingqian, WANG Jiongkun, CAI Jiye, et al. Nanostructure and force spectroscopy analysis of human peripheral blood CD4+T cells using atomic force microscopy[J].Biochem Biophys Res Commun,2008,374 (1):90-94.
[40]Gabriel Y.H.Lee,Chwee T. Lim.Biomechanics approaches to studying human diseases[J].Trends in Biot-echnology,2007,25(3):111-118.
[41]Subra Suresh.Biomechanics and biophysics of cancer cells[J].Acta Materialia,2007,55(12):3989-4014.
[42]Engin Ulukaya, Ferda Ozdikicioglu, Arzu Yilmaztepe Oral, et al. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested[J]. Toxicology in Vitro,2008,22(1):232-239.
[43]赵斌,葛金芳,朱娟娟,等.小议在MTT法测细胞增殖抑制率中IC50的计算方法[J].安徽医药,2007,11(9)：834-836.
[44]Jin Chen, Xing-Hua Feng, Jian Shi. The anti-nociceptive effect of BmK AS, a scorpion active polypeptide, and the possible mechanism on specifically modulating voltage-gated Na+ currents in primary afferent neurons [J].Peptides,2006,27(9): 2182-2192.
[45]Brabec V. DNA modifications by antitumor platinum and rugthenium compounds their recognition and repair [J]. Prog Nucleic Acid Res Mol Biol,2002,71:1-68.
[46]Lean Teik Ng, Lien-Chai Chiang, Yu-Tseng Lin,et al. Antiproliferative and apoptotic effects of Tetrandrine on different human heaptoma cell lines[J]. The American Journal of Chinese Medicine,2006,34(1):125-135.
[47]Jia Wei, Baorui Liu,Lifeng Wang,et al. Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines[J]. Cancer Chemotherapy and Pharmacology,2007,60:703-711.
[48]Jinyi Wang,Zongfang Wan. Atomic force microscope study of tumor cell membranes following treatment with anti-cancer drugs[J]. Biosensors and Bioelectronics,2009,25 (4):721-727.
[49]Shripad Kondra,Jummi Laishram. Integration of confocal and atomic force microscopy images[J].Journal of Neuroscience Methods,2009,177(1):94-107.
[1]张丽龙.新型异黄酮化合物F11的药物设计、抗癌活性与遗传生殖毒性研究[D].北京：第三军医大学,2007.
[2]Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ,Workman P. Anticancer agents targetingsignaling molecules and cancer cell environment:challenges for drug development?[J]. Nail Cancer Inst 1999,91:1281-1287.
[3]Nava Zaarur,Vladimir L. Gabai, John A.Targeting Heat Shock Response to Sensitize Cancer Cells to Proteasome and Hsp90 Inhibitors[J]. Cancer Res 2006;66:1783-1791
[4]Stang K, Gunther C, Fran KT, et al. Inhibition of the ubiquitin-proteosome pat hway induces differential heat shockprotein response in cardiomyocytes and renders early cardiac protection[J]. Biochem Biophys Res Commun,2002,3:542-549;
[5]Rutherford SL, Lindquist S. HSP90 as a capacitor for morphologicalevolution[J]. Nature,1998,6709:336-342;
[6]Bagatell R, Whitesell L. Altered hsp90 function in cancer:a unique therapeutic opportunity [J]. Mol Cancer Ther,2004; 8:1021-1030;
[7]Pearl LH, Prodromou C. Structure, function, and mechanism of the Hsp90 molecular chaperone[J]. Adv Protein Chem,2001,59:157-164;
[8]PrattW B. The Hsp902based chaperone system:involvement in signal transduction from a variety of hormone and growth factor receptors[J]. Proc Soc Exp B iolMed,1998,217:420-431;
[9]Workman P. Combinatorial attack on multistep oncogenesis by inhibitingthe Hsp90 molecular chaperone[J]. Cancer Lett,2004,2:149-157.
[10]Ferrarini M, Hehai S, Zocchi MR, et al. Unusual expression and localization of heat-shock proteins in human tulrlor cells [J]. Int Jcancer,1992,51(4):613-619.
[11]Kaelin WG Jr. Taking aim at novel molecular targets in cancer therapy[J].J Clin Invest,1999,104(11):1495.
[12]Ochel HJ, Schulte TW, Nguyen P, et al. The benzoquinone ansamycin geldanamycinstimulates proteolytic degradation of focal adhesion kinase [J]. Mol GenetMetab,1999,66(1):24-30.
[13]Supko JG, Hickman RL, Grever MR, et al. Precl finical pharmacologicevaluation of geldnamycin as an antitumor agent [J].Cancer Chemother Pharmaco,1995,36(4): 305-315.
[14]Kwon HJ,Yoshida M, Fukui Y, et al. Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol [J]. Cancer Res,1992,24: 6926-6930.
[15]Goetz MP, Toft DO, Ames MM, et al. The Hsp90 chaperone comp lex as a novel target for cancer therapy [J]. Ann Oncol,2003,14(8):1169-1176.
[16]Schulte TW, Neckers LM.Thebenzoquinoneansamyeinl7-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin[J].Cancer Chemother Pharmacol,1998,4:273-279.
[17]Chiosis G, Tao H. Purine-scaffold Hsp90 inhibitors[J]. IDrugs,2006,11:778-782.
[18]Thomas E, Barta JM, Veal JW. Rice, et al. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90[J]. Bioorg Med Chem Lett,2008,18:3517-3521.
[19]Sarat C, Ayana S, Qing Ye, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers[J]. Clin Cancer Res,2008,1:240-248;
[20]Yutaka O, Teru H, Paul S, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK[J]. Blood, 2009,4:846-855;
[21]Sharom FJ. ABC multidrug transporters:structure, function and role in chemoresistance[J]. Pharmacogenomics Jan;2008,9:105.
[22]Stephen G. Aller1, Jodie Yu1, Andrew Ward2, et al. Structure of P-glycoprotein Reveals a Molecular Basis for PolySpecific Drug Binding[J]. Science.2009 March 27; 323(5922):1718-1722.
[23]Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter[J]. Annual Review of Biochemistry.1993;62:385-427
[24]Gatlik-Landwojtowicz E, Aanismaa P, Seelig A. Quantification and characterization of P-glycoprotein-substrate interactions[J].Biochemistry,2006 45:3020.
[25]Piskunova TS, Yurova MN, Ovsyannikov AI, et al.Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice[J]. Curr Gerontol Geriatr Res.2008:754190.
[26]Espinoza LA, Smulson ME, Chen Z. Prolonged poly(ADP-ribose) polymerase-1 activity regulates JP-8-induced sustained cytokine expression in alveolar macrophages[J]. Free radical biology & medicine,2007,42 (9):1430-40.
[27]Zerfaoui M, Suzuki Y, Naura AS, et al. Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells:Differential requirement for PARP-1 expression and interaction[J]. Cell Signal,2008.20 (1):186-94.
[28]Liu X D, Sun H, Liu G T. Tumor chemosensitization strategies based on apoptosis manipulations [J]. Chin Pharmacol Bull,2009,25(10):1261-4.
[29]Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer:drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21.
[30]Bieling P, Laan L, Schek H, Munteanu EL, Sandblad L, Dogterom M, Bruimer D, Surrey T. Reconstitution of a microtubule plus-end traeking system in vitro.Nature.2007,450(7172):1100-1105.
[31]Barta TE, Veal JM, Rice JW, et al. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett,2008,18,3517-3521;